Sentynl Therapeutics, Inc.
Sentynl Therapeutics, Inc., headquartered in the United States, is a pioneering biopharmaceutical company dedicated to advancing innovative therapies for patients with rare diseases. Founded in 2017, Sentynl has quickly established itself in the industry, focusing on the development and commercialisation of unique treatment options that address unmet medical needs. With a strong emphasis on precision medicine, Sentynl's core products include specialised therapies that leverage cutting-edge research and technology. The company is committed to improving patient outcomes through its robust pipeline and strategic partnerships. Notably, Sentynl has achieved significant milestones in regulatory approvals, positioning itself as a leader in the biopharmaceutical sector. As it continues to expand its operational reach, Sentynl Therapeutics remains at the forefront of transforming healthcare for those affected by rare conditions.
DitchCarbon Score
How does Sentynl Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sentynl Therapeutics, Inc.'s score of 25 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sentynl Therapeutics, Inc.'s reported carbon emissions
Sentynl Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor do they have specified reduction targets or climate pledges. This absence of data suggests that the company may still be in the early stages of formalising its climate commitments or reporting on its carbon footprint. In the context of the biopharmaceutical industry, many companies are increasingly focusing on sustainability and reducing their carbon emissions across all scopes. While Sentynl Therapeutics has not yet disclosed specific initiatives or targets, it is essential for organisations in this sector to align with industry standards and best practices in climate action. As the company progresses, it may consider establishing measurable reduction targets and engaging in initiatives that contribute to a more sustainable future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sentynl Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
